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Summary To ensure access to essential medicines for disadvantaged populations there are at least three conditions
to be met: drugs prices must be affordable for poor countries; research and development of drugs for
tropical diseases must take place; and there is a need for health exceptions to trade agreements.
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In its daily work, Me Âdecins Sans Frontie Áres (MSF) is
constantly facing the ravages of infectious diseases and
the lack of access to health care and medicines among
populations in distress. In 1998, a campaign was launched
to ensure access to essential drugs for disadvantaged
populations (www.accessmed-msf.org). When in October
1999 MSF was awarded the Nobel Peace Prize, it choose to
consecrate theprize money toneglected diseases highlighted
by the campaign, which is constituted of three pillars.
Overcoming the barriers of access to medicines
A number of (new) drugs for treating tropical diseases are
tooexpensiveandothersarenolongerproducedbecausethe
market is not pro®table. According to the pro®t rationale
that currently prevails, a medicine must be lucrative to be
produced commercially. Many factors in¯uence access to
effective medicines (Pe Âcoul et al. 1999), including quality of
diagnosis; accurate prescribing, selection, distribution and
dispensing of drugs; drug quality; capacities of health
systems and budgets; and lack of research and development
(R&D). But one of the fundamental barriers to access is
price. Several factors can in¯uence the price of a medicine,
including patents, generic competition, production cost,
taxes, tariffs and mark-ups, and R&D costs.
MSF is currently identifying manufacturers who are
producing affordable quality drugs, negotiating better
prices with manufacturers and supporting the countries'
efforts to improve access to essential drugs. In the long
term, MSF is looking for ways to restart the production of
drugs that are no longer being manufactured. MSF also
advocates a global tiered pricing system based on the
principle of equity that would offer lower drug prices to
developing countries, making drugs truly affordable to
patients, while maintaining prices in the industrialized
world. This pricing system should bene®t all developing
countries and should be accessible for health care providers
outside the public sector as well. But MSF also appreciates
companies' concerns that equity pricing may be used to
demand lower prices in industrialized countries. Therefore,
it is willing to launch a public campaign to support the
principle that developing countries should pay less for
essential medicines and it accepts provisions to prevent the
re-import of equity-priced drugs into high-income markets.
For the poorest countries, international funding will still
be critical to subsidize drug purchases. MSF advocates
more means for the procurement of drugs that could give
leverage to the purchasing power of developing countries
and donors.
To improve global price transparency, MSF supports the
development of a data base on drug prices, quality and
patent status. This data base should be managed by a UN
agency, with patent information provided by the World
Intellectual Property Organization.
Stimulating research and development of medicines
Research into tropical diseases has ground to a virtual halt.
While pharmaceutical companies argue that patents are
essential to continue ®nancing R&D, they actually neglect
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developing countries. Of the 1223 new drugs developed
since 1975, only 11 directly target a tropical disease
(Trouiller & Olliaro 1999).
Using data gathered from the ®eld, MSF tries to highlight
the lack of effectiveness of old treatments and the limited
resources currently allocated to tropical diseases. MSF
wants to stimulate R & D efforts that focus on an
internationally agreed-upon, need-driven agenda, which
from the beginning aims at developing drugs that are
effective, safe, affordable and easy to use. The applied
strategies should preferentially be disease-speci®c.
Furthermore, new funding has been called for, as well as
the revision of legal and regulatory frameworks and a
special international treaty to guarantee adequate R & D
for neglected diseases in the future. MSF believes that
investing in developing countries' capacity to research,
develop and produce their own medicines will be a key part
of a sustainable solution.
Health exceptions to trade agreements
The World Trade Organization's (WTO) agreement, Trade
Related Aspects of Intellectual Property Rights (TRIPS), is
the most important international agreement on protection
of patents, copyrights, and trademarks. It is setting the
rules for the sale of drugs within and between countries,
treating medicines like any other product. Drug patents
confer a market monopoly to pharmaceutical companies
for any invention for a minimum of 20 years [World
Health Organization (WHO) 1997; WTO 1995]. Only on
expiry of the patent, other companies are allowed to
produce it as a `generic' drug. The resulting competition
between several manufacturers often leads to a dramatic
fall in price. Therefore, TRIPS is expected to affect the
price of new life-saving drugs negatively and to further
restrict access to patients in developing countries
(Dumoulin 2000). MSF does not oppose patents but it
contests the dire imbalance caused by TRIPS between the
sanctity of patents and the health of people.
Nonetheless, within TRIPS there are safeguards to
address this imbalance and MSF is supporting countries to
use these safeguards, which include parallel imports,
compulsory licences and strategies to accelerate the intro-
duction of generics (Correa 2000a,b). Parallel imports is
cross-border trade in a branded product without the
manufacturer's permission ± or, shopping for the best price
on the global market. It is an attractive option for
developing countries when the same branded medicine is
being sold for different prices in different markets. Com-
pulsory licences are provisions in patent law that allow
public authorities to grant licenses to a third party without
the consent of the patent holder. Patent holders receive
adequate compensation. Compulsory licences may be
issued on various grounds of general interest, including
public health, and are a common feature of patent law.
Compulsory licences can be used as a leverage to introduce
generics, to keep the possibility of generic competition real
and to put pressure on companies to grant voluntary
licences. Export under compulsory licence must be allowed
for this safeguard to be meaningful for the poorest
countries. Generic substitution and competition is allowed
by the TRIPS agreement. Appropriate formulation and
implementation of national legislation and regulations is
needed in order to avoid any delay. The use of exceptions
to exclusive rights, which permit early testing and approval
of generics (`Bolar' provisions), voluntary licences and
compulsory licences can also facilitate the prompt intro-
duction of generics.
To ensure that trade policies do not harm public health,
the ®rst step is to guarantee that safeguards are included in
the national legislation of developing countries. Among
WTO member states, most developing countries had to
implement TRIPS in their national legislation by 2000.
Some countries that did not grant patents on pharmaceu-
ticals before 1995 can do so up to 2005, and least-
developed countries up to 2006. The second step is to
support developing countries in using the options when
needed. The duty of countries to protect the public health
of their people must take precedence over the right of the
commercial sector to make pro®ts.
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